Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 25;14(5):e25340.
doi: 10.7759/cureus.25340. eCollection 2022 May.

Spironolactone Versus Oral Contraceptive Pills in the Treatment of Adolescent Polycystic Ovarian Syndrome: A Systematic Review

Shriya Rajashekar  1 , Suganya Giri Ravindran  1 , Meghana Kakarla  1 , Musa Ausaja Gambo  1 , Mustafa Yousri Salama  1 , Nathalie Haidar Ismail  2 , Pardis Tavalla  1 , Pulkita Uppal  1 , Shaza A Mohammed  1 , Pousette Hamid  3
Affiliations
Review

Spironolactone Versus Oral Contraceptive Pills in the Treatment of Adolescent Polycystic Ovarian Syndrome: A Systematic Review

Shriya Rajashekar et al. Cureus. .

Abstract

Polycystic ovarian syndrome (PCOS) is a multi-system endocrinopathy that affects women of reproductive age. Due to features that coincide with puberty, it frequently remains undiagnosed in adolescent females. The lack of evidence on management alternatives has resulted in significant variation in practice. This systematic review evaluated the therapeutic advantages and adverse effects of a regularly used therapy option, combined oral contraceptive pills (COC/OCP) with spironolactone (SP), a newer alternative that may be used alone or in conjunction with other drugs to treat adolescent PCOS. A literature search was conducted using PubMed, PubMed Central, Scopus, and Google Scholar. It was restricted to studies published in English between 2021 and 2011 that discussed the management of adolescent PCOS with COC, SP, or both. The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Two reviewers independently examined the content of the included studies using appropriate quality assessment tools. Four meta-analyses, four randomized controlled trials (RCTs), and one traditional review were found to be eligible. After extensive analysis, we concluded that SP, alone or in combination, is far safer than COC. However, COC treats more PCOS-associated symptoms than SP, including acne and menstrual irregularities, while also providing contraceptive benefits. However, SP monotherapy is cardioprotective and therapeutic when combined with other drugs. Long-term COC use has been linked to an increased risk of venous thromboembolism, hypertension, dyslipidemia, low-density lipoprotein (LDL) elevation, dysglycemia, and cancer in women.

Keywords: adolescent; adolescent pcos; coc; combined oral contraceptive pills; ocp; oral contraceptive pills; pcos; polycystic ovarian syndrome; spiomet; spironolactone.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Pathophysiology of PCOS
FSH: follicular stimulating hormone; LH: luteinising hormone; SHBG: sex hormone-binding globulin; T2DM: type 2 diabetes mellitus; E1: estrone; E2: estradiol; IGF1: insulin-like growth factor 1; PCOS: polycystic ovarian syndrome. Created with BioRender.com by the authors.
Figure 2
Figure 2. PRISMA 2020 flow diagram
PRISMA: Preferred reporting items for systematic reviews and meta-analysis. The figure was created by the authors.
See this image and copyright information in PMC

References

    1. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Escobar-Morreale HF. Nat Rev Endocrinol. 2018;14:270–284. - PubMed
    1. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Azziz R, Carmina E, Dewailly D, et al. J Clin Endocrinol Metab. 2006;91:4237–4245. - PubMed
    1. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. Ndefo UA, Eaton A, Green MR. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737989/ P T. 2013;38:336–355. - PMC - PubMed
    1. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. Hum Reprod. 2016;31:2841–2855. - PubMed
    1. Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease. McGowan MP. Curr Treat Options Cardiovasc Med. 2011;13:289–301. - PubMed

LinkOut - more resources